Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Therapy of THP-00101, THP-00102, and THP-00103 in Type 2 Diabetes Mellitus and Essential Hypertension
TCTR20241006001Phase 3Recruiting
- Sponsor
- THPharm
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin, telmisartan in type 2 diabetes mellitus (T2DM), essential hypertension, sponsored by THPharm. Started Apr 2025; status: recruiting.
02
Drugs
dapagliflozintelmisartan
03
Conditions
type 2 diabetes mellitus (T2DM)essential hypertension
Beyond the preview
Go deeper on TCTR20241006001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20241006001.